

Victoria Cardona

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8233347/publications.pdf>

Version: 2024-02-01

144
papers

9,440
citations

41344

49
h-index

40979

93
g-index

161
all docs

161
docs citations

161
times ranked

7171
citing authors

#	ARTICLE	IF	CITATIONS
1	Commercialized kits to assess T-cell responses against SARS-CoV-2 S peptides. A pilot study in health care workers. <i>Medicina Clínica</i> , 2022, 159, 116-123.	0.6	40
2	Assessment of the Control of Allergic Rhinitis and Asthma Test (CARAT) using MASK-air. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 343-345.e2.	3.8	11
3	EAACI guidelines: Anaphylaxis (2021 update). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 357-377.	5.7	193
4	Development and validation of combined symptom& medication scores for allergic rhinitis*. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2147-2162.	5.7	32
5	Molecular diagnosis contribution for personalized medicine. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2022, Publish Ahead of Print, .	2.3	1
6	Allergen immunotherapy in MASK&air users in real&life: Results of a Bayesian mixed&effects model. <i>Clinical and Translational Allergy</i> , 2022, 12, e12128.	3.2	9
7	Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK&air^Â real&world data. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2699-2711.	5.7	17
8	Comparison of rhinitis treatments using <sc>MASK</sc>&air& data and considering the minimal important difference. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3002-3014.	5.7	8
9	COVID&19 pandemic: Practical considerations on the organization of an allergy clinic& An EAACI/ARIA Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 648-676.	5.7	79
10	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 168-190.	5.7	46
11	Phenotype and risk factors of venom-induced anaphylaxis: A&case-control study of the European Anaphylaxis Registry. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 653-662.e9.	2.9	40
12	ARIA&EAACI statement on asthma and COVID&19 (June 2, 2020). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 689-697.	5.7	57
13	Digital technology for anaphylaxis management impact on patient behaviour: A randomized clinical trial. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1507-1516.	5.7	6
14	Peanut&induced anaphylaxis in children and adolescents: Data from the European Anaphylaxis Registry. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1517-1527.	5.7	39
15	Food&dependent NSAID&induced hypersensitivity (FDNIH) reactions: Unraveling the clinical features and risk factors. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1480-1492.	5.7	12
16	A Proposal from the Montpellier World Health Organization Collaborating Centre for Better Management and Prevention of Anaphylaxis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 676-683.e1.	3.8	11
17	Diagnosing, managing and preventing anaphylaxis: Systematic review. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1493-1506.	5.7	40
18	COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee. <i>World Allergy Organization Journal</i> , 2021, 14, 100517.	3.5	121

#	ARTICLE	IF	CITATIONS
19	Wheat Anaphylaxis in Adults Differs from Reactions to Other Types of Food. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2844-2852.e5.	3.8	28
20	Heterogeneity of the pharmacologic treatment of allergic rhinitis in Europe based on MIDAS and OTCims platforms. <i>Clinical and Experimental Allergy</i> , 2021, 51, 1033-1045.	2.9	8
21	Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA- ² EAACI- ² GA ² LEN consensus. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2354-2366.	5.7	31
22	One-Dilution Rapid Desensitization Protocol to Chemotherapeutic and Biological Agents: A Five-Year Experience. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4045-4054.	3.8	14
23	ARIA- ² EAACI care pathways for allergen immunotherapy in respiratory allergy. <i>Clinical and Translational Allergy</i> , 2021, 11, e12014.	3.2	24
24	Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 563-576.	3.8	5
25	Food-induced anaphylaxis morbidity: Emergency department and hospitalization data support preventive strategies. <i>Pediatric Allergy and Immunology</i> , 2021, 32, 1730-1742.	2.6	6
26	Anaphylaxis viewed by experts: unmet needs. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2021, 21, 435-441.	2.3	1
27	Update on latex allergy: New insights into an old problem. <i>World Allergy Organization Journal</i> , 2021, 14, 100569.	3.5	31
28	Management of anaphylaxis due to COVID-19 vaccines in the elderly. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2952-2964.	5.7	16
29	Validity, reliability, and responsiveness of daily monitoring visual analog scales in MASK- ^{air} ®. <i>Clinical and Translational Allergy</i> , 2021, 11, e12062.	3.2	31
30	The role of mobile health technologies in allergy care: An EAACI position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 259-272.	5.7	95
31	Fatal Anaphylactic Shock Induced by Intravenous Gelatin Colloid: A Postmortem Allergological Work-up. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2020, 30, 143-145.	1.3	1
32	Secondary prevention measures in anaphylaxis patients: Data from the anaphylaxis registry. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 901-910.	5.7	10
33	Cypress Pollen Allergy in a Mediterranean Area. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2020, 30, 67-69.	1.3	3
34	World Allergy Organization Anaphylaxis Guidance 2020. <i>World Allergy Organization Journal</i> , 2020, 13, 100472.	3.5	461
35	Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study. <i>Clinical and Translational Allergy</i> , 2020, 10, 62.	3.2	34
36	A WAO-ARIA-GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020. <i>World Allergy Organization Journal</i> , 2020, 13, 100091.	3.5	76

#	ARTICLE	IF	CITATIONS
37	Molecular diagnosis usefulness for idiopathic anaphylaxis. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2020, 20, 248-252.	2.3	7
38	Is diet partly responsible for differences in COVID-19 death rates between and within countries?. <i>Clinical and Translational Allergy</i> , 2020, 10, 16.	3.2	97
39	IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper. <i>World Allergy Organization Journal</i> , 2020, 13, 100080.	3.5	245
40	Clinical Features, Inducers and Treatment of Anaphylaxis in Latin America and Spain. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, AB77.	2.9	0
41	Correlation between work impairment, scores of rhinitis severity and asthma using the MASK ^{air} App. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1672-1688.	5.7	32
42	In vivo diagnostic test allergens in Europe: A call to action and proposal for recovery plan. An EAACI position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2161-2169.	5.7	23
43	ARIA-Leitlinie 2019: Behandlung der allergischen Rhinitis im deutschen Gesundheitssystem. <i>Allergologie</i> , 2020, 43, 43-72.	0.1	0
44	Characteristics, quality of life and control of respiratory allergic diseases caused by house dust mites (HDMs) in Spain: a cross-sectional study. <i>Clinical and Translational Allergy</i> , 2019, 9, 39.	3.2	3
45	Kounis Syndrome. <i>Current Treatment Options in Allergy</i> , 2019, 6, 289-296.	2.2	2
46	ARIA guideline 2019: treatment of allergic rhinitis in the German health system. <i>Allergo Journal International</i> , 2019, 28, 255-276.	2.0	22
47	Drug-induced anaphylaxis ² elicitors, mechanisms and diagnosis. <i>Allergo Journal International</i> , 2019, 28, 327-329.	2.0	7
48	Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases ² Meeting Report (Part 1). <i>Journal of Thoracic Disease</i> , 2019, 11, 3633-3642.	1.4	11
49	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. <i>Clinical and Translational Allergy</i> , 2019, 9, 44.	3.2	87
50	Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases ² Meeting Report (Part 2). <i>Journal of Thoracic Disease</i> , 2019, 11, 4072-4084.	1.4	15
51	The Use of Molecular Allergy Diagnosis in Anaphylaxis: a Literature Review. <i>Current Treatment Options in Allergy</i> , 2019, 6, 142-155.	2.2	0
52	Changing the history of anaphylaxis mortality statistics through the World Health Organization's International Classification of Diseases ¹¹ . <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 627-633.	2.9	46
53	Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. <i>Clinical and Translational Allergy</i> , 2019, 9, 16.	3.2	81
54	Anaphylactic shock to meropenem with ertapenem tolerance: A case report. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2057-2058.	3.8	4

#	ARTICLE	IF	CITATIONS
55	2019 ARIA Care pathways for allergen immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2087-2102.	5.7	140
56	Delayed drug hypersensitivity to bortezomib: Desensitization and tolerance to its analogue carfilzomib. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1384-1386.	5.7	5
57	Time to revisit the definition and clinical criteria for anaphylaxis?. World Allergy Organization Journal, 2019, 12, 100066.	3.5	137
58	Mobile Technology in Allergic Rhinitis: Evolution in Management or Revolution in Health and Care?. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2511-2523.	3.8	44
59	Biologics and anaphylaxis. Current Opinion in Allergy and Clinical Immunology, 2019, 19, 439-446.	2.3	15
60	<sc>ARIA</sc> pharmacy 2018 –Allergic rhinitis care pathways for community pharmacy– Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1219-1236.	5.7	52
61	Adherence to treatment in allergic rhinitis using mobile technology. The <sc>MASK</sc> Study. Clinical and Experimental Allergy, 2019, 49, 442-460.	2.9	73
62	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. Journal of Allergy and Clinical Immunology, 2019, 143, 864-879.	2.9	103
63	ARIA-Versorgungspfade f¼r die Allergenimmuntherapie 2019. Allergologie, 2019, 42, 404-425.	0.1	2
64	ARIA guideline 2019: treatment of allergic rhinitis in the German health system. Allergologie Select, 2019, 3, 22-50.	3.1	70
65	Clinical trials in allergen immunotherapy: current concepts and future needs. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1775-1783.	5.7	52
66	Factors increasing the risk for a severe reaction in anaphylaxis: An analysis of data from The European Anaphylaxis Registry. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1322-1330.	5.7	176
67	The urgent need for a harmonized severity scoring system for acute allergic reactions. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1792-1800.	5.7	79
68	Critical view of anaphylaxis epidemiology: open questions and new perspectives. Allergy, Asthma and Clinical Immunology, 2018, 14, 12.	2.0	59
69	Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (<sc>MACVIA</sc> –<sc>ARIA</sc>) –<sc>EIP</sc> on <sc>AHA</sc> Twinning Reference Site (<sc>GARD</sc> research demonstration project). Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 77-92.	5.7	54
70	Challenges in the implementation of the <sc>EAACI AIT</sc> guidelines: A situational analysis of current provision of allergen immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 827-836.	5.7	44
71	Current practice of allergy diagnosis and the potential impact of regulation in Europe. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 323-327.	5.7	17
72	Perspectives in allergen immunotherapy: 2017 and beyond. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 5-23.	5.7	76

#	ARTICLE	IF	CITATIONS
73	Food-induced fatal anaphylaxis: From epidemiological data to general prevention strategies. <i>Clinical and Experimental Allergy</i> , 2018, 48, 1584-1593.	2.9	120
74	MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. <i>Clinical and Translational Allergy</i> , 2018, 8, 45.	3.2	104
75	Phenotypes, endotypes and biomarkers in anaphylaxis: current insights. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2018, 18, 370-376.	2.3	24
76	Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study. <i>World Allergy Organization Journal</i> , 2018, 11, 15.	3.5	33
77	Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A <scp>EUFOREA</scp> – <scp>ARIA</scp> – <scp>EPOS</scp> – <scp>AIRWAYS ICP</scp> statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1297-1305.	5.7	130
78	The SQ House Dust Mite SLIT-Tablet Is Well Tolerated in Patients with House Dust Mite Respiratory Allergic Disease. <i>International Archives of Allergy and Immunology</i> , 2017, 174, 35-44.	2.1	21
79	Applying prevention concepts to anaphylaxis: A call for worldwide availability of adrenaline auto-injectors. <i>Clinical and Experimental Allergy</i> , 2017, 47, 1108-1114.	2.9	32
80	Validation of the <scp>MASK</scp> – rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control. <i>Clinical and Experimental Allergy</i> , 2017, 47, 1526-1533.	2.9	75
81	Vaccination and allergy: <scp>EAACI</scp> position paper, practical aspects. <i>Pediatric Allergy and Immunology</i> , 2017, 28, 628-640.	2.6	103
82	Safety of Adrenaline Use in Anaphylaxis: A Multicentre Register. <i>International Archives of Allergy and Immunology</i> , 2017, 173, 171-177.	2.1	35
83	New trends in anaphylaxis. <i>Allergo Journal International</i> , 2017, 26, 295-300.	2.0	15
84	In-flight allergic emergencies. <i>World Allergy Organization Journal</i> , 2017, 10, 15.	3.5	24
85	Immunotherapy in allergic rhinitis and lower airway outcomes. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 35-42.	5.7	40
86	Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA. <i>Journal of Nutrition, Health and Aging</i> , 2017, 21, 92-104.	3.3	47
87	CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel Network) Good Practice in allergic rhinitis: a SUNFRIL report. <i>Clinical and Translational Allergy</i> , 2017, 7, 37.	3.2	36
88	The Mast Cell, Contact, and Coagulation System Connection in Anaphylaxis. <i>Frontiers in Immunology</i> , 2017, 8, 846.	4.8	60
89	Lettuce Allergy Is a Lipid Transfer Syndrome-Related Food Allergy With a High Risk of Severe Reactions. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2017, 27, 98-103.	1.3	13
90	Component-Resolved Diagnosis of Dog Allergy. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2017, 27, 185-187.	1.3	9

#	ARTICLE	IF	CITATIONS
91	Relevance of Allergenic Sensitization to <i>Cynodon dactylon</i> and <i>Phragmites communis</i> : Cross-reactivity With Pooideae Grasses. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2016, 26, 295-303.	1.3	5
92	Particularities of allergy in the Tropics. <i>World Allergy Organization Journal</i> , 2016, 9, 20.	3.5	101
93	Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies. <i>Clinical and Translational Allergy</i> , 2016, 6, 41.	3.2	24
94	ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. <i>Clinical and Translational Allergy</i> , 2016, 6, 47.	3.2	121
95	Current Trends in Prevalence and Mortality of Anaphylaxis. <i>Current Treatment Options in Allergy</i> , 2016, 3, 205-211.	2.2	14
96	Safe and Time-Saving Desensitization Protocol to Intravenous Etoposide. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 793-794.	3.8	7
97	Component-resolved diagnosis in anaphylaxis. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2016, 16, 244-249.	2.3	17
98	Relevance of food allergy in the assessment of NSAID-related reactions. <i>Clinical and Translational Allergy</i> , 2015, 5, O22.	3.2	0
99	Definition, Epidemiology, and Pathogenesis. <i>Current Treatment Options in Allergy</i> , 2015, 2, 207-217.	2.2	4
100	Biomarkers of anaphylaxis, beyond tryptase. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2015, 15, 329-336.	2.3	28
101	Diagnostic test allergens used for <i>in vivo</i> diagnosis of allergic diseases are at risk: a European Perspective. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1329-1331.	5.7	43
102	Specific molecular allergic sensitisation patterns in pediatric polysensitized patients. <i>World Allergy Organization Journal</i> , 2015, 8, A152.	3.5	0
103	Enfermedad de riesgo vital de origen respiratorio o alérgico en el deporte. <i>Apuntes Medicine De L'Esport</i> , 2015, 50, 35-42.	0.5	3
104	Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 1031-1043.e6.	2.9	120
105	IgE-Mediated Allergic Reactions after the First Administration of Glatiramer Acetate in Patients with Multiple Sclerosis. <i>International Archives of Allergy and Immunology</i> , 2014, 165, 244-246.	2.1	11
106	Management of anaphylaxis: a systematic review. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 168-175.	5.7	109
107	First European data from the network of severe allergic reactions (NORA). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 1397-1404.	5.7	247
108	The epidemiology of food allergy in Europe: a systematic review and meta-analysis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 62-75.	5.7	407

#	ARTICLE	IF	CITATIONS
109	Component resolved diagnosis: when should it be used?. <i>Clinical and Translational Allergy</i> , 2014, 4, 28.	3.2	70
110	Acute and long-term management of food allergy: systematic review. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 159-167.	5.7	74
111	Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 1026-1045.	5.7	809
112	Primary prevention of food allergy in children and adults: systematic review. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 581-589.	5.7	168
113	International consensus on (ICON) anaphylaxis. <i>World Allergy Organization Journal</i> , 2014, 7, 9.	3.5	360
114	EAACI Food Allergy and Anaphylaxis Guidelines: diagnosis and management of food allergy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 1008-1025.	5.7	979
115	The epidemiology of anaphylaxis in Europe: a systematic review. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 1353-1361.	5.7	306
116	Allergology in Europe, the blueprint. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 1211-1218.	5.7	22
117	Association of thromboxane A1 synthase (TBXAS1) gene polymorphism with acute urticaria induced by nonsteroidal anti-inflammatory drugs. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 989-991.	2.9	21
118	Knowledge of the Ibero-American Physicians On Anaphylaxis: Results of the Ibero-American Online Survey for Physicians On the Management and Treatment of Anaphylaxis (IOSPTA) - Latin American Society of Allergy, Asthma & Immunology (LASAAI). <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, AB220.	2.9	1
119	Validation of the first treatment-specific questionnaire for the assessment of patient satisfaction with allergen-specific immunotherapy in allergic patients: The ESPIA questionnaire. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 1539-1546.e2.	2.9	20
120	Is faster safer? Cluster versus short conventional subcutaneous allergen immunotherapy. <i>Immunotherapy</i> , 2013, 5, 1295-1303.	2.0	7
121	Usefulness and Limitations of Sequential Serum Tryptase for the Diagnosis of Anaphylaxis in 102 Patients. <i>International Archives of Allergy and Immunology</i> , 2013, 160, 192-199.	2.1	144
122	Knowledge of anaphylaxis among ibero-American physicians: results of the Ibero-American Online Survey for Physicians on the management and treatment of anaphylaxis (IOSPTA) -Latin American society of Allergy, Asthma & Immunology (LASAAI). <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2013, 23, 441-3.	1.3	4
123	Spirometric Maneuvers and Inhaled Salbutamol Do Not Affect Exhaled Nitric Oxide Measurements among Patients with Allergic Asthma. <i>Respiration</i> , 2012, 83, 239-244.	2.6	11
124	Co-factor enhanced food allergy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 1316-1318.	5.7	104
125	Development of a disease-specific quality of life questionnaire for adult patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-QoL): Spanish multi-centre research project. <i>Health and Quality of Life Outcomes</i> , 2012, 10, 82.	2.4	52
126	EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. <i>Clinical and Translational Allergy</i> , 2012, 2, 20.	3.2	97

#	ARTICLE	IF	CITATIONS
127	Research needs in allergy: an EAACI position paper, in collaboration with EFA. Clinical and Translational Allergy, 2012, 2, 21.	3.2	127
128	One hundred years of allergen immunotherapy <sc>E</sc>uropean <sc>A</sc>cademy of <sc>A</sc>llergy and <sc>C</sc>linical <sc>I</sc>mmunology celebration: review of unanswered questions. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 462-476.	5.7	56
129	Analysis of mite allergic patients in a diverse territory by improved diagnostic tools. Clinical and Experimental Allergy, 2012, 42, 1129-1138.	2.9	45
130	Development of a questionnaire to assess patient satisfaction with allergen-specific immunotherapy in adults: item generation, item reduction, and preliminary validation. Patient Preference and Adherence, 2011, 5, 239.	1.8	3
131	Generalised delayed desquamative exanthema after intradermal testing with betalactam antibiotics. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 702-703.	5.7	6
132	Welcome to <i>Clinical and Translational Allergy</i>. Clinical and Translational Allergy, 2011, 1, 1.	3.2	16
133	Allergic diseases in the elderly. Clinical and Translational Allergy, 2011, 1, 11.	3.2	57
134	Anaphylactic reaction due to razor shell. Clinical and Translational Allergy, 2011, 1, .	3.2	0
135	Fighting allergies beyond symptoms: The European Declaration on Immunotherapy. European Journal of Immunology, 2011, 41, 2802-2804.	2.9	12
136	Frozen fruit skin prick test for the diagnosis of fruit allergy. Asian Pacific Journal of Allergy and Immunology, 2010, 28, 275-8.	0.4	1
137	Oestrogenâ€dependent hereditary angioâ€oedema with normal C1 inhibitor: description of six new cases and review of pathogenic mechanisms and treatment. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 735-741.	5.7	29
138	Allergenicity and cross-reactivity of Senecio pollen: identification of novel allergens using the immunoproteomics approach. Clinical and Experimental Allergy, 2008, 38, 1048-1060.	2.9	15
139	Anafilaxia, el riesgo del infradiagnÃ³stico. Semergen, 2008, 34, 17-19.	0.5	1
140	IMMEDIATE-TYPE HYPERSENSITIVITY REACTION TO LEVOTHYROXINE AND DESENSITIZATION. Annals of Allergy, Asthma and Immunology, 2008, 100, 513-514.	1.0	13
141	Acquired angioedema associated with hereditary angioedema due to C1 inhibitor deficiency. Journal of Investigational Allergology and Clinical Immunology, 2008, 18, 126-30.	1.3	5
142	Development and Validation of a New Spanish Instrument to Measure Health-Related Quality of Life in Patients with Allergic Rhinitis: The ESPRINT Questionnaire. Value in Health, 2007, 10, 466-477.	0.3	30
143	SAFETY OF EBASTINE. Annals of Allergy, Asthma and Immunology, 2005, 94, 407.	1.0	0
144	B-lymphocytes and co-stimulatory molecules in Mycobacterium tuberculosis infection. International Journal of Tuberculosis and Lung Disease, 2004, 8, 98-105.	1.2	20